Prognostic factors of cervical cancer recurrence.

Guskova, Ekaterina; Неродо, Г. А.; Guskova, Nailya; Chernikova, Natalia V.; Poryvaev, Yuriy A.; Nikitina, Vera P.; Verenikina, Ekaterina V.

doi:10.1200/jco.2016.34.15_suppl.e17025

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of recurrence for cervical cancer for all tumor stages and forms of therapy is between 22 and 31% 19 , 20 . Known risk factors for local/locoregional recurrence are the FIGO stage (tumor diameter, parametrial tumor invasion, metastatic involvement of pelvic lymph nodes), younger age (< 45 years), the histological subtype, and lymphatic invasion L1 20 – 24 .…”

Section: Guidelinementioning

confidence: 99%

“…Die Rezidivrate beim Zervixkarzinom über alle Tumorstadien und alle Therapieformen beträgt zwischen 22 und 31% 19 , 20 . Als Risikofaktoren für ein lokales/lokoregionäres Rezidiv konnten das FIGO-Stadium (Tumordurchmesser, parametrale Tumorinvasion, metastatischer Befall pelviner Lymphknoten), jüngeres Alter (< 45), der histologische Subtyp, sowie Lymphgefäßinvasion L1 nachgewiesen werden 20 – 24 .…”

Section: Leitlinieunclassified

See 1 more Smart Citation

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities

Fehm

Stübs

Koch

et al. 2022

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Aim This is an update of the interdisciplinary S3-guideline on the Diagnosis, Therapy and Follow-up of Cervical Cancer (AWMF Registry No. 032/033OL), published in March 2021. The work on the updated guideline was funded by German Cancer Aid (Deutsche Krebshilfe) as part of the German Guideline Program in Oncology. The guideline was coordinated by the German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, DGGG) and the Working Group on Gynecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG). Method The process used to update the 2014 S3-guideline was based on an appraisal of the available evidence using the criteria of evidence-based medicine, adaptations of existing evidence-based national and international guidelines or – if evidence was lacking – on the consensus of the specialists involved in compiling the update. After an initial review of the current literature was carried out according to a prescribed algorithm, several areas were identified which, in contrast to the predecessor version from September 2014, required new recommendations or statements which would take account of more recently published literature and the recent appraisal of new evidence. Recommendations The short version of this guideline consists of recommendations and statements on palliative therapy and follow-up of patients with cervical cancer. The most important aspects included in this updated guideline are the new FIGO classification published in 2018, the radical open surgery approach used to treat cervical cancer up to FIGO stage IB1, and the use of the sentinel lymph node technique for tumors ≤ 2 cm. Other changes include the use of PET-CT, new options in radiotherapy (e.g., intensity-modulated radiotherapy, image-guided adaptive brachytherapy), and drug therapies to treat recurrence or metastasis.

show abstract

Section: Guidelinementioning

confidence: 99%

Section: Leitlinieunclassified

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities

Fehm

Stübs

Koch

et al. 2022

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives

Yang

Liu

Ektare

et al. 2021

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background Bevacizumab remains the most widely used and most thoroughly characterized angiogenesis inhibitor for a range of advanced cancers. Bevacizumab-bvzr (Zirabev ® ), a biosimilar of bevacizumab, was recently approved by the US Food and Drug Administration (FDA), which provides a less costly option. This study aimed to evaluate the financial impact of introducing bevacizumab-bvzr from US commercial and Medicare payer perspectives. Methods A Microsoft Excel-based budget impact model was developed over a 5-year time horizon. Target population was patients to be treated with bevacizumab for FDA-approved indications. Drug costs (2020 US$) were based on average sales price and wholesale acquisition cost, accounting for payer-specific reimbursement models and provider settings. Drug dosing and duration were based on prescribing information and pivotal trial publications. Results In a hypothetical 10-million-member health plan, 503 and 723 patients were estimated to be treated with bevacizumab in year 1 and year 5, respectively. Assuming an annual market shift of 1.7%,

show abstract

Malignant Neoplasms as the Most Priority Medical and Social Issue of the Healthcare System

Vaninov

2019

BSP

View full text Add to dashboard Cite

The article provides literature data on the trends of malignant neoplasms not only in the world but also in the Kyrgyz Republic. Malignant neoplasms are a global problem in public health, occupy a leading place for the causes of mortality. In 2018, more than 18 million new cases of cancer were diagnosed worldwide, more than 9.6 million people died, and the total number of patients increased to 43 million. According to forecasts, by 2030, the number of new cases of cancer will increase to 26.4 million per year, and the number of deaths — up to 17 million. The epidemiological situation of cancer remains unfavorable, both in Russia and around the world. In the Russian Federation, there is an increase in cancer incidence from 363.0 in 2010 to 425.3 in 2018 per 100,000 population. Moreover, the growth trend is observed in all regions of the country. In the Kyrgyz Republic, the incidence of malignant neoplasms increased from 83.1 in 2010 to 90.3 per 100,000 of the population in 2018. This indicator is growing in Chui, Naryn and Batken regions, as well as in Osh, and in other regions, there is a slight decrease in the indicator. In the structure of oncological morbidity, the first place is occupied by breast cancer (206‱), the second place — cancer of the cervix (153‱), and the third place — cancer of the stomach (117‱). It should be noted that in Russia for every 100 patients who died from malignant neoplasms, 10.7 were not registered. The mortality rate in the Kyrgyz Republic has somewhat stabilized, both in the republic as a whole and in individual regions, and in 2018 amounted to 56.3 per 100,000 of the population (56.4 in 2017). In the female population, 1st place is occupied by breast cancer — 605‱, 2nd place — by the cervix (153‱), 3rd place — by the stomach (71‱). One of the most common forms of malignant neoplasms of the organs of the reproductive system is cervical cancer, which takes 2nd place in frequency and 3rd place in mortality from cancer in women. The analysis of morbidity and mortality from malignant neoplasms in various countries showed that screening and early detection, as well as timely and effective treatment, are necessary to reduce mortality.

show abstract

Prognostic factors of cervical cancer recurrence.

Cited by 3 publications

References 0 publications

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives

Malignant Neoplasms as the Most Priority Medical and Social Issue of the Healthcare System

Contact Info

Product

Resources

About